ArticleScientific reports2025
Matrix metalloproteinases as diagnostic and prognostic biomarkers in skin cutaneous melanoma and squamous cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Insulin Resistance and Cutaneous Squamous Cell Carcinoma: A Narrative Review of Molecular Mechanisms.Iranian journal of medical sciences · 2026Review
- Advancing precision immuno-oncology in melanoma: the synergistic convergence of personalized neoantigen vaccines and multi-omics biomarker profiling.Frontiers in immunology · 2026Review
- Phenotype switching in highly invasive resistant to vemurafenib and cobimetinib melanoma cells.Cell communication and signaling : CCS · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin cutaneous melanoma (SKCM) and squamous cell carcinoma (SCC) are two prevalent forms of skin cancer, both characterized by extensive remodeling of the extracellular matrix (ECM), which facilitates tumor progression and metastasis. To investigate ECM-related gene expression alterations in SCC and assess their diagnostic and prognostic relevance in SKCM by integrating transcriptomic data with clinical outcomes. RNA-sequencing data from NCBI Gene Expression Omnibus (GEO) were analyzed to identify differentially expressed genes in SCC. Key findings were validated in The Cancer Genome Atlas (TCGA) SKCM dataset. Functional enrichment and protein-protein interaction (PPI) analyses were conducted to identify ECM-related pathways and hub genes. Matrix metalloproteinases MMP7, MMP11, and MMP14 were significantly upregulated in SCC and showed elevated expression in primary SKCM tumors, confirmed by RT-qPCR analysis. Functional enrichment revealed dysregulation of ECM-receptor interaction and IL-17 signaling pathways. PPI analysis identified MMP14 as central hub interacting with TIMPs, CD44, and FURIN. Kaplan-Meier survival analysis showed that elevated MMP11 and MMP14 expression correlated with worse overall survival. ROC curve analysis confirmed their strong diagnostic value, with MMP14 achieving an AUC of 0.955. MMP7, MMP11, and MMP14 play key roles in skin cancer progression. They show strong potential as diagnostic and prognostic biomarkers and may serve as therapeutic targets in SCC and SKCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.